Uncategorized
Sustained-release Dextenza meets endpoints for post-cataract surgery pain
NEW ORLEANS — Sustained-release dexamethasone was superior to placebo in managing pain and preventing inflammation after cataract surgery, a speaker told colleagues here.At the American Society of Cataract and Refractive Surgery meeting, Joseph Gira, MD, reported results of two phase 3 prospective, multicenter, randomized studies of Dextenza (sustained-release dexamethasone intracanalicular depot, Ocular Therapeutix).